Biotech Values

[BTH]

Blade, I completely agree with you on this.

They need to retain as much as their best compound as possible. They should be working as hard as possible to unload Rindopepimut (if they even can) for some money. Hell.. they should be on the phone to Merck Kgaa at this point...those German Merck guys seem to want a piece of every crappy unproven compound and dole out plenty of money for them (not saying Rindo is crappy, but, you get the point).

I'd be very disappointed if they got $75 million upfront for '011. They'd piss through that rather quickly.

I would rather see them finance the company through secondaries and retain 100% of it, like Ariad has done with Ponatinib.